This video reviews controversies in the treatment of early-stage hormone receptor (HR)-positive breast cancer.
In this video, Vered Stearns, MD, of Johns Hopkins School of Medicine in Baltimore, Maryland, reviews controversies in the treatment of early-stage hormone receptor (HR)-positive breast cancer.
Stearns gave a presentation on this topic at the 2017 San Antonio Breast Cancer Symposium (SABCS), held December 5–9 in San Antonio, Texas.
Belzutifan Improves PFS Across Subgroups for Advanced ccRCC
July 12th 2024“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.